ReviewClinical reviews in allergy & immunology2026
Dendritic cells as orchestrators in the allergen-specific immunotherapy of allergic diseases.
Review in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) play a pivotal role in regulating immune responses, encompassing both tolerance and activation. Dysregulation of DC function is fundamental in the development of allergic conditions, underscoring their significance as a major focus for allergen-specific immunotherapy (AIT). This review systematically delineates the intricate landscape of DC subsets, comprising conventional DCs, plasmacytoid DCs, monocyte-derived DCs, and Langerhans cells, elucidating their specific contributions to either fostering Th2-driven inflammation or driving regulatory T cell generation. We dissect the multi-layered mechanisms through which DCs orchestrate immune tolerance, spanning cytokine signaling, metabolic reprogramming, epigenetic remodeling, and migratory dynamics. Additionally, the article extensively evaluates and contrasts the distinct roles of DC subsets and their modes of antigen presentation across various AIT administration routes (e.g. subcutaneous, sublingual, oral, epidermal, intranasal, intralymphatic and intratonsillar). Lastly, we highlight next-generation DC-targeted strategies, such as nanoparticle-mediated delivery systems and genetic engineering methodologies, designed to reprogram DCs toward a stable tolerogenic phenotype and enhance therapeutic efficacy. Translating these preclinical advances into personalized clinical interventions represents a pivotal frontier for establishing durable immune tolerance in allergic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.